News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website

 

The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma

Al's Comment:

 This article says that although radiation improves survival for glioblastomas, it also makes the tumor harder to treat. They found that by adding the drug trifluoperazine  (which is approved for psychiatric disorders) at the time of radiation, they were able to preserve the benefit of radiation but stop the conversion that causes the tumor cells to be harder to treat.  In mice, it resulted in longer survivals!    

There is a different clinical trial now of another dopamine receptor antagonist, Onc-201, being tested for H3K27M mutant gliomas. They are testing it during and after radiation, as well as only after. Comparing the 2 may show the effect described in the article- hopefully longer survivals!


Posted on: 08/24/2020

The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740